BioMedNewsBreaks

MondayMay 11, 2026 9:40 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident

NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections. To view the full press release, visit https://ibn.fm/OYkof ABOUT…

Continue Reading

ThursdayMay 07, 2026 11:44 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Expands Concierge Cardiology Footprint With Atelier Health Agreement

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with Beverly Hills-based concierge medical practice Atelier Health, expanding the company’s launch footprint into Southern California and completing its initial targeted markets alongside New York metro, Dallas and South Florida as it advances commercialization of its cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology. To view the full press release, visit https://ibn.fm/wwNAd About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

Continue Reading

ThursdayMay 07, 2026 11:32 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Clearance for Depression and Suicidality Trial 

NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to initiate a Phase 2/3 clinical trial evaluating NRX-101 in patients with treatment-resistant major depressive disorder and suicidality receiving active or sham transcranial magnetic stimulation, with the study to be conducted by subsidiary NRx Defense Systems and expected to enroll 240 participants across academic, HOPE Therapeutics and military treatment facility sites. To view the full press release, visit https://ibn.fm/DxPva About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders,…

Continue Reading

WednesdayMay 06, 2026 1:22 pm

BioMedNewsBreaks — AI Meets Multi-Omics: Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Earlier, More Precise Cardiac Insights

Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular disease remains one of the most serious and costly health challenges worldwide, driving an urgent need for earlier detection and more precise, personalized treatment strategies. “Cardio Diagnostics Holdings is focused on addressing this need by developing advanced solutions that leverage artificial intelligence (‘AI’) and multi-omic biomarkers to deliver actionable insights from a simple blood sample, enabling more informed and timely care cardiac care decisions,” the publication reads. “Despite advances in medicine, a key challenge in managing cardiovascular disease is that it often develops silently over…

Continue Reading

WednesdayMay 06, 2026 12:35 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Completes $12.5M N2B Asset Transfer to Lunai Bioworks 

Oncotelic Therapeutics (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system IP within biodefense and Alzheimer’s disease fields in exchange for $12.5 million in Series B convertible preferred stock. The agreement establishes an initiative focused on CNS-targeted therapeutics while supporting the company’s strategy to monetize its portfolio and retain control of core assets. The N2B platform enables intranasal delivery directly to the central nervous system, bypassing the blood-brain barrier to support rapid therapeutic action and targeted neurological engagement, with applications in biodefense medical countermeasures and neurodegenerative conditions. Under the agreement, Lunai Bioworks will develop the platform…

Continue Reading

WednesdayMay 06, 2026 12:12 pm

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study

VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, achieving 97% specificity and identifying 86% of cases, advancing development of a blood-based liquid biopsy test for feline cancer. The company said the technology addresses a significant unmet need in veterinary medicine and represents a commercial opportunity, with potential milestone payments and future revenue generation, as it works toward product commercialization and expands its presence in the growing companion animal oncology market. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5…

Continue Reading

TuesdayMay 05, 2026 9:50 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee Act in summer 2026, supported by stability data from multiple registration batches and a successful third-party manufacturing audit. To view the full press release, visit https://ibn.fm/yEXl3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone).…

Continue Reading

MondayMay 04, 2026 10:55 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing

CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation from institutional healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. The company said proceeds will support its strategy to acquire and advance new assets, along with working capital and general corporate purposes, while A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction. To view the full press release, visit https://ibn.fm/usrIh About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies…

Continue Reading

MondayMay 04, 2026 9:30 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Redesigned Platform and Multi-Site Digital Ecosystem

HealthLynked (OTCQB: HLYK) announced the launch of a redesigned consumer platform and multi-site digital ecosystem aimed at improving healthcare access, reducing inefficiencies and enhancing engagement across patients, providers, partners and investors. The company said the new architecture includes dedicated platforms for consumer access, provider engagement, business partnerships and investor relations, supporting its strategy to build a scalable, consumer-driven healthcare platform with national reach and future AI-driven capabilities. To view the full press release, visit https://ibn.fm/cJfsm About HealthLynked Corp. HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for…

Continue Reading

ThursdayApr 30, 2026 1:59 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample,” reads a recent article. “At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional…

Continue Reading